For every drug that makes it to the finish line and into the clinic, another nine do not succeed. This alarming failure rate can be traced back to an overreliance on two-dimensional (2D) cell cultures or animal models that do not closely mimic complex human biology, often leading to inaccurate predictions of a drug’s potential and extended drug development timelines.
New and innovative three-dimensional (3D) models – such as organoids – enable more accurate predictions of patient responses to novel medicines early on, while also streamlining drug development time and cost.
In this session, leading experts from the industry discuss the promise of 3D biology and organoids for advancing drug discovery. They examine how to overcome challenges involved in 3D biology and what the future of organoid research will look like.
